How should I manage my basal insulin (Tresiba, insulin degludec) and high‑dose insulin regimen (hardline) before surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Perioperative Management of Tresiba (Insulin Degludec)

For patients on Tresiba (insulin degludec) before surgery, reduce the dose to 75-80% of the usual dose on the evening before surgery, hold all oral diabetes medications the morning of surgery, and monitor blood glucose every 2-4 hours while NPO with correction doses of short- or rapid-acting insulin as needed. 1

Specific Dosing Algorithm for Tresiba

The most recent 2025 ADA guidelines provide clear direction for long-acting basal insulin analogs like Tresiba:

  • Evening before surgery: Give 75-80% of the usual Tresiba dose 1
  • Morning of surgery: Do NOT give additional Tresiba
  • Target blood glucose: 100-180 mg/dL perioperatively 1

This recommendation is based on evidence showing that a 25% dose reduction (i.e., giving 75% of usual dose) the evening before surgery achieves better perioperative glucose control with lower hypoglycemia risk compared to giving the full dose 2.

Evidence Supporting the 75-80% Dose Reduction

A key study demonstrated that patients receiving approximately 75% of their usual basal insulin dose (specifically 60-87% range, with mean of 73%) the evening before surgery had:

  • The highest proportion (78%) achieving target glucose range
  • Significantly lower hypoglycemia rates compared to those taking 100% of their dose
  • Better outcomes than those taking lower percentages or no insulin 3

This is more conservative than older 2018 guidelines that recommended 60-80% dosing 4, reflecting evolving evidence toward slightly higher doses to prevent perioperative hyperglycemia while still minimizing hypoglycemia risk.

Critical Perioperative Monitoring

While NPO (nothing by mouth):

  • Monitor blood glucose every 2-4 hours 1
  • Administer short- or rapid-acting insulin for correction as needed
  • Do NOT aim for tighter targets than 100-180 mg/dL, as stricter goals (80-180 mg/dL) increase hypoglycemia without improving outcomes 2

Additional Medication Management

Hold these medications:

  • Metformin: Hold on day of surgery 1
  • SGLT2 inhibitors: Discontinue 3-4 days before surgery 1
  • All other oral glucose-lowering agents: Hold morning of surgery 1

Understanding "Hardline" Insulin Regimens

If "hardline" refers to intensive basal-bolus insulin therapy (basal insulin plus premeal rapid-acting insulin):

Continue basal insulin at reduced dose (75-80%) as above, but:

  • Hold all prandial (mealtime) insulin doses while NPO 1
  • Use only correction doses of short- or rapid-acting insulin for hyperglycemia while fasting
  • Resume basal-bolus regimen once oral intake resumes

The evidence strongly supports maintaining basal insulin coverage perioperatively, as basal-bolus regimens show improved glycemic outcomes and lower complication rates compared to correction-only sliding scale approaches in noncardiac surgery 2.

Common Pitfalls to Avoid

  1. Do NOT completely hold Tresiba - This leads to perioperative hyperglycemia and increased surgical complications
  2. Do NOT give the full usual dose - This significantly increases hypoglycemia risk (patients taking 100% of usual dose had highest hypoglycemia rates) 3
  3. Do NOT use CGM alone for glucose monitoring during surgery - Point-of-care blood glucose testing is required 1
  4. Do NOT transfer Tresiba from pen to syringe - This can cause overdosage and severe hypoglycemia 5

Special Considerations for Tresiba

Tresiba has unique pharmacokinetic properties:

  • Ultra-long duration of action (>42 hours) 6
  • Low day-to-day variability in absorption 7, 6
  • Can be dosed at any time of day in outpatients, but perioperative dosing should follow the evening-before protocol 5

These properties make the 75-80% dose reduction particularly appropriate, as the long half-life provides sustained basal coverage even with dose reduction, while minimizing hypoglycemia risk during the fasting perioperative period.

Preoperative Optimization

Ideally, A1C should be <8% before elective surgery whenever possible 1. If A1C is significantly elevated, consider delaying elective procedures to optimize glycemic control, as this reduces surgical complications, infections, and mortality 2.

References

6
Research

In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025

Related Questions

For an outpatient with a blood glucose of 492 mg/dL, what rapid‑acting and basal insulin types and dosing should be used?
A patient reports a blood glucose reading >450 mg/dL, is asymptomatic, and has just started 12 units of insulin with education on insulin use and diet; what additional steps should be taken?
In a 59-year-old male with type 2 diabetes, weight 117 kg, currently on insulin glargine (Lantus) 80 units daily and receiving continuous TPN from 8 pm to 8 am containing 300 g dextrose with 123 units of regular insulin, insulin sensitivity factor 10 mg/dL per unit, insulin‑to‑carbohydrate ratio 4 g/unit, and fasting blood glucose values of 177, 209, 226, 215, and 261 mg/dL overnight, what should the basal insulin (insulin glargine) dose and the regular insulin amount in the TPN be adjusted to?
What is the recommended 7‑point blood glucose charting protocol for a patient on insulin therapy?
How should severe hyperglycemia be managed in a patient whose blood glucose is 596 mg/dL after receiving 12 units of lispro (insulin lispro)?
How should a wound that has not healed for three months after a cat scratch be evaluated and managed?
When should a controller inhaler (inhaled corticosteroid) be prescribed for an adult with asthma?
When should residents of a skilled nursing facility be tested for influenza, and when is it appropriate to start empiric antiviral therapy without testing?
How can I configure an automated literature update on platelet‑rich plasma (PRP) infiltration, and what 20 clarification questions should be asked to define its scope, schedule, and output format?
What is the appropriate management of tracheobronchitis?
How should an isolated right bundle branch block be managed in an asymptomatic patient?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.